[SEN]HLB, the postponement of the Jeungsun committee will be postponed again… Spreading the atmosphere of participation in grants

[SEN]HLB, the postponement of the Jeungsun committee will be postponed again… Spreading the atmosphere of participation in grants

by

[서울경제TV=배요한기자] Securities and Futures Commission HLB (028300)It is expected to postpone the proposal of the agenda again. In the securities industry, observations are cautious about whether the judgment of the financial authorities is changing when the deliberation schedule is delayed again.

HLB’s stock price from the 90,000 won level fell to 6,600 won (February 18) as a media reported that it is being investigated by the financial authorities, resulting in a market cap of close to 2 trillion won (including affiliates) within three days. Evaporated.

HLB recently announced a 100% free-of-charge increase to improve shareholder value as the stock price plummeted. Thanks to this news, the stock price, which plunged nearly 40%, succeeded in rebounding to the mid-70,000 won range. The company is expressing a strong determination to resolve the suspicion and improve shareholder value, and there is a widespread atmosphere among shareholders to participate in the free increase.

While HLB is confident in his vocation, the anxiety of shareholders is gradually decreasing as the positive opinions of new drug licensing experts from the FDA continue. However, opinions are constantly raised in the industry that a quick conclusion from the Jeungseon Committee is necessary.

An industry official said, “If the issue prolongs for any reason, the stock price may fluctuate. If the issue continues to be inconclusive, the volatility of the stock price will increase, so the financial authorities need to quickly deal with the agenda. “

Meanwhile, with HLB HLB Life Science (067630)All of them have decided on March 16 as the new stock allocation date, and the expected date for listing is April 1. HLB’s share issuance excess amounted to 370 billion won in 2019 (estimated 770 billion won in 2020), and HLB Life Sciences will use 26.5 billion won and 23.5 billion won respectively through this increase. Seems to be enough.

/Bae Yohan [email protected]

< 저작권자 ⓒ 서울경제, 무단 전재 및 재배포 금지 >

Source